1 / 7

Aliskiren and Valsartan for Antihypertensive Therapy Trial

Aliskiren and Valsartan for Antihypertensive Therapy Trial. Aliskiren and Valsartan for Antihypertensive Therapy Trial. Presented at the American College of Cardiology Annual Scientific Session March 2007 Presented by Dr. Suzanne Oparil.

kaloosh
Download Presentation

Aliskiren and Valsartan for Antihypertensive Therapy Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aliskiren and Valsartan for Antihypertensive Therapy Trial Aliskiren and Valsartan for Antihypertensive Therapy Trial Presented at the American College of Cardiology Annual Scientific Session March 2007 Presented by Dr. Suzanne Oparil

  2. Aliskiren and Valsartan for Antihypertensive Therapy Trial: Background • Valsartan is an angiotensin receptor blocker (ARB), and aliskiren is a new direct renin inhibitor that has just been approved by the US FDA. • The goal of this trial was to evaluate treatment with aliskiren, valsartan, or the combination of the two compared with placebo among patients with mild to moderate hypertension. ACC 2007

  3. Aliskiren and Valsartan for Antihypertensive Therapy Trial: Study Design 1797 patients of mean age 52 years with mild to moderate hypertension (diastolic blood pressure (DBP) > 95 and < 220 mm Hg) prior to randomization Placebo-controlled. Randomized. Blinded. Mean follow-up 8 weeks. 39% female. R 1-2 week period of washout from prior therapy and a 3-4 week run-in period Aliskiren 150 mg n=437 Valsartan 160 mg n=455 Aliskiren + Valsartan 150 mg + 160 mg n=446 Placebo n=459 4 weeks, double dosages Aliskiren + Valsartan 300 mg + 320 mg n=446 Placebo n=459 Aliskiren 300 mg n=437 Valsartan 320 mg n=455 mos. or yrs. follow-up 4 more weeks • Primary Endpoint: Reduction in mean sitting DBP • Secondary Endpoint: Reduction in mean sitting SBP, response rate, achievement of blood pressure control (<140/90 mm Hg) ACC 2007

  4. Aliskiren and Valsartan for Antihypertensive Therapy: 4 Week Outcomes *p<0.0001 vs. placebo †p<0.001 vs. aliskiren/valsartan ACC 2007

  5. Aliskiren and Valsartan for Antihypertensive Therapy: 8 Week Outcomes *p<0.0001 vs. placebo †p<0.001 vs. aliskiren/valsartan ACC 2007

  6. Aliskiren and Valsartan for Antihypertensive Therapy: Summary • Among patients with mild to moderate hypertension, aliskiren, valsartan, and the combination of the two were associated with greater reductions in blood pressure compared with placebo at 8 wks, with the largest reductions seen in the combination group. • Both aliskiren and valsartan are inhibitors of the renin-angiotensin-aldosterone system, but act at different points in the system, with aliskiren acting at the point of activation. ACC 2007

  7. Aliskiren and Valsartan for Antihypertensive Therapy: Summary • Both agents were effective in reducing blood pressure, but the combination of the two agents appeared to be additive. • Work is ongoing into whether there will be improved organ protection with aliskiren alone and in combination. ACC 2007

More Related